10-K: Guardian Pharmacy Services Navigates Post-IPO Landscape with 2024 Annual Report

Guardian Pharmacy Services reports its first full year results post-IPO, highlighting revenue growth alongside increased expenses and a net loss.

Summary

• Guardian Pharmacy Services, Inc. released its 10-K filing for the fiscal year ended December 31, 2024.
• The company reported a revenue increase of 17.4% to $1.228 billion, driven by both acquisitions and organic growth.
• Cost of goods sold also increased by 17.4%, maintaining a consistent percentage of revenue at 80.1%.
• Selling, general, and administrative expenses saw a significant increase of 83.6%, primarily due to share-based compensation expenses related to the IPO.
• The company experienced a net loss of $71.033 million, influenced by the increased operating expenses.
• Adjusted EBITDA increased to $90.834 million, reflecting core operating performance.
• As of December 31, 2024, the company served approximately 186,000 residents in approximately 7,000 LTCFs across 38 states.
• The company's growth strategy focuses on increasing the number of residents served through organic growth, greenfield start-ups, and acquisitions.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue growth and Adjusted EBITDA are positive, the net loss and increased expenses raise concerns. The company's future outlook and growth strategy provide some optimism, but the risks and challenges in the industry need to be considered.

Positives

• Revenue increased by 17.4% to $1.228 billion, indicating strong business growth.
• Adjusted EBITDA increased to $90.834 million, reflecting core operating performance.
• The company completed acquisitions of various pharmacy operations during the year, expanding its market presence.
• The company has a robust M&A function with a demonstrated track record of both successful identification of integration of superior qualified pharmacies that are compatible with our platform.

Negatives

• The company reported a net loss of $71.033 million.
• Selling, general, and administrative expenses increased significantly due to share-based compensation related to the IPO.
• The company is a controlled company within the meaning of the corporate governance standards of NYSE.

Risks

• Intense competition may erode profit margins.
• The COVID-19 pandemic negatively impacted LTCFs and harmed our business.
• The impact of ongoing healthcare reform efforts on our business cannot accurately be predicted.
• If we fail to comply with Medicare and Medicaid regulations, we may be subjected to reduction in reimbursement, overpayment demands, or loss of eligibility to participate in these programs.
• Cybersecurity attacks or other data security incidents could disrupt our operations and expose us to regulatory fines or penalties, liability or reputational harm.
• Acquisitions and strategic alliances that we have made or may make in the future could require significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
• The market price of shares of our Class A common stock has experienced, and may in the future experience, substantial volatility.

Future Outlook

The company expects to continue its growth strategy through organic expansion, greenfield start-ups, and acquisitions, focusing on increasing the number of residents served.

Industry Context

The company operates in the competitive long-term care pharmacy services market, facing competition from national, regional, and local providers. The aging demographics and increasing acuity of residents in LTCFs are driving demand for specialized pharmacy services.

Comparison to Industry Standards

• The company believes it is the largest LTCF pharmacy in the United States in terms of market share serving ALF/MC, with an approximate 12.6% market share nationally.
• IBISWorld estimated that the U.S. institutional pharmacy market revenues for 2024 would be approximately $24.8 billion.
• The company competes with large national providers including Omnicare, Inc. and PharMerica Corporation, in addition to local and regional pharmacies in each of our markets, including Remedi SeniorCare, PharmCareUSA and Polaris Pharmacy Services.

Related Party Transactions

• The company provides pharmaceutical related services to facilities owned or managed by certain Class B Common Stock stockholders and non-controlling interest holders, which are considered to be related parties.
• Revenues attributed to these facilities was $23,450 and $23,256 for the years ended December 31, 2023 and 2024, respectively.

Stakeholder Impact

• Shareholders may be concerned about the net loss and increased expenses, but reassured by the revenue growth and Adjusted EBITDA.
• Employees may be affected by changes in compensation and benefits.
• Customers (LTCFs and residents) can expect continued service and potential improvements in care coordination.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to focus on increasing the number of residents served through organic growth, greenfield start-ups, and acquisitions.
• The company will continue to monitor and assess the impact of healthcare reform efforts and regulations on its business.
• The company will continue to invest in technology and services capabilities to expand its business in the post-acute care sector.

Key Dates

Keywords

pharmacy services, long-term care, financial results, acquisitions, revenue, EBITDA, IPO, Guardian Pharmacy, LTCF, share-based compensation